High CD123 expression levels were consistently found on NPM1-mutated CD34+ CD38- putative LSC, suggesting that immunotherapies targeting CD123 could potentially be particularly effective in NPM1-mutated AML patients [1,65,87]. This evidence concerns the gene CD34 and acute myeloid leukemia.